Creo Medical Sustainability Profile
Creo Medical, a pioneering medical device company headquartered in Great Britain, is at the forefront of advanced energy-based surgical solutions. Founded in 2015, the company has rapidly established itself in the medical technology industry, focusing on innovative treatments for gastrointestinal and oncological conditions. With a strong presence in Europe and expanding operations in the United States and Asia, Creo Medical is renowned for its unique combination of microwave and radiofrequency technologies. Their flagship products, including the CROMA™ and the Speedboat™ devices, offer minimally invasive options that enhance patient outcomes and reduce recovery times. Recognised for its commitment to innovation, Creo Medical has achieved significant milestones, positioning itself as a leader in the field of surgical endoscopy. The company continues to drive advancements in medical technology, making a meaningful impact on patient care worldwide.
DitchCarbon Score
How does Creo Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Creo Medical's score of 45 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Creo Medical's reported carbon emissions
In 2024, Creo Medical reported total carbon emissions of approximately 1,045,200 kg CO2e, comprising 354,200 kg CO2e from Scope 1 (mobile combustion), 85,200 kg CO2e from Scope 2 (purchased electricity), and 600,800 kg CO2e from Scope 3 (business travel). This represents a significant increase in emissions compared to 2023, where total emissions were about 1,044,400 kg CO2e, with Scope 1 at 207,400 kg CO2e, Scope 2 at 67,300 kg CO2e, and Scope 3 at 263,700 kg CO2e. In the UK, emissions for 2023 were reported at approximately 586,500 kg CO2e, with Scope 1 emissions of 46,500 kg CO2e, Scope 2 at 26,500 kg CO2e, and Scope 3 at 533,000 kg CO2e. This indicates a focus on business travel as a significant contributor to their carbon footprint. Creo Medical has set ambitious climate commitments, aiming for a minimum annual emissions reduction of 7% across all scopes from 2023 to 2030. Additionally, they are targeting net-zero emissions for Scope 1 and Scope 2 by 2027. These initiatives reflect a proactive approach to addressing climate change and reducing their overall carbon footprint. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Creo Medical Group PLC.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 207,400 | 000,000 |
| Scope 2 | 67,300 | 00,000 |
| Scope 3 | 263,700 | 000,000 |
How Carbon Intensive is Creo Medical's Industry?
How Carbon Intensive is Creo Medical's Location?
Creo Medical's Scope 3 Categories Breakdown
Creo Medical's Scope 3 emissions, which increased by 128% last year and increased by approximately 128% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 58% of total emissions under the GHG Protocol, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Creo Medical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Creo Medical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
